Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of breviscapine as chemotherapeutic drug cardiotoxicity prevention and treatment drug

A technology of breviscapine and myocardial toxicity, which is applied in the application field of breviscapine as a chemotherapeutic drug for the prevention and treatment of myocardial toxicity. Improve myocardial damage and reduce oxidative stress

Pending Publication Date: 2021-08-13
TSINGHUA UNIV +2
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no research and development report on the value of breviscapine in the treatment of myocardial injury caused by chemotherapy drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of breviscapine as chemotherapeutic drug cardiotoxicity prevention and treatment drug
  • Application of breviscapine as chemotherapeutic drug cardiotoxicity prevention and treatment drug
  • Application of breviscapine as chemotherapeutic drug cardiotoxicity prevention and treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1. Comparison of the effect of breviscapine on H9c2 cell activity by different anthracyclines (doxorubicin, epirubicin)

[0061] H9c2 cardiomyocytes were diluted with medium to 10 6 / ml of cell suspension, and inoculated in 96-well plates, adding 100 μL of cell suspension to each well, cultured for 24 hours, and then treated with drugs. Divided into blank control group (pure DMEM), model group 1 (5 μM DOX), model group 2 (5 μM EPI), positive control group (20 μM Dexra), 5 μM DOX+20 μM Dexra group, 5 μM DOX+Breviscapine group (breviscapine 10 / 20 / 50 / 100 / 200μM), 5μM EPI+Breviscapine group (breviscapine 200μM). After culturing for 24 hours, CCK-8 cell viability was used to measure the absorbance at 450 nm using a microplate reader to calculate the cardiomyocyte activity.

[0062] The result is as figure 1 As shown, compared with the control group cell activity of 94.08%, the 5 μM model group 1 cell activity was 23.11%, and the 5 μM model group 2 cell activity wa...

Embodiment 2

[0065] Example 2, the effect of breviscapine on reducing the leakage of lactate dehydrogenase (LDH) in adriamycin H9c2 cardiomyocytes

[0066] H9c2 cardiomyocytes were diluted with medium to 10 6 / ml of cell suspension, and inoculated in 6-well plates, adding 2ml of cell suspension to each well, cultured for 24h, and then treated with drugs. Set up a blank control group (pure DMEM), a model group (5 μM DOX), a positive control group (20 μM Dexra), and a DOX+Breviscapine group (5 μM DOX+200 μM Breviscapine). After culturing for 24 h, the LDH detection kit was used for determination. The results show( figure 2 ) The leakage rate of LDH in different medication groups was significantly lower than that in the model group.

Embodiment 3

[0067] Example 3, the effect of breviscapine on the level of superoxide dismutase (SOD) in adriamycin H9c2 cardiomyocytes

[0068] Superoxide anion (O 2-. ), O 2-. Nitroblue tetrazole can be reduced to form blue formazan, which absorbs at 560nm. The same treatment method was adopted as in Example 2. After culturing for 24 hours, the operation was performed according to the instructions of the CuZn / Mn-SOD activity detection kit. The results show( image 3 ), the DOX+Breviscapine group can significantly increase the activity of total SOD, which is significantly higher than that of the model group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines for preventing and treating cardiotoxicity, and particularly relates to application of breviscapine as a chemotherapeutic medicine for preventing and treating cardiotoxicity. According to the defect of the existing listed product-dexrazolidone, the breviscapine shows the characteristics and advantages of the breviscapine in prevention and treatment application in the aspects of cardiotoxicity protection of anthracycline chemotherapeutics and the like, and meanwhile, the breviscapine is low in raw material cost, good in safety basis and suitable for industrial production. The compound can be used as an active component or a medicine composition component for myocardial protection of anthracycline chemotherapeutics, the cardiotoxicity caused by the chemotherapeutics is reduced, and the life quality and the treatment prognosis of tumor patients are improved.

Description

technical field [0001] The invention belongs to the technical field of drugs for preventing and treating cardiotoxicity, and in particular relates to the application of breviscapine as a drug for preventing and treating cardiotoxicity of chemotherapy drugs. Background technique [0002] With the increasing incidence of cancer, the cycle and cumulative dosage of antineoplastic drugs including anthracycline chemotherapy drugs are increasing, and the adverse reactions of chemotherapy drugs are becoming more and more prominent. Among them, the harm caused by myocardial injury is the most concerned. Therefore, With regard to the new clinical needs and discipline trends of chemotherapy drugs for myocardial injury, the new discipline of oncology and cardiology has developed rapidly in recent years. Its purpose is how to evaluate, prevent and treat cardiovascular adverse reactions caused by chemotherapy drugs while ensuring the anti-tumor effect of chemotherapy drugs. [0003] At p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/04
CPCA61K31/7048A61P9/04
Inventor 邢东明李梦娇卢琦叶婷张钰坤邹林峰高远真原阳张仁帅王超钟英杰
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com